Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Overview of attention for article published in Multiple Sclerosis Journal, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 20 X users

patent: 5 patents
wikipedia: 6 Wikipedia pages
reddit: 1 Redditor
guideline: 1 clinical guideline source

Readers on

mendeley: 299 Mendeley

So far, Altmetric has seen 24 X posts from 20 X users, with an upper bound of 24,683 followers.

@hthsci4bb3 EVIDENCE: Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis https://t.co/XAwnVhu1yk

@SFHunterMDPhD Cladribine extension trial: https://t.co/2rRoKXtcE7

@DrKantor cladribine extension study was pretty damn good for only taking a few tablets for two years: https://t.co/2rRoKXtcE7

RT @MSJ_Research: Durable clinical benefits of #cladribine without ongoing treatment in #RRMS #MSJ @merckgroup https://t.co/B0go6wWJ7y http…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 20 additional X posts.